

CURRICULUM VITAE



PERSONAL INFORMATION

Name **FIorenza SANTAMARIA**
E-mail **fiorenza.santamaria@uniroma1.it**
Nationality **Italian**
Date of birth **26/04/1990**

EDUCATION AND TRAINING

01/11/2022 – nowadays

University of Rome “La Sapienza”

Ph.D. in “*Network Oncology and Precision Medicine*”. Division of Experimental Medicine

Coordinator: prof.ssa Elisabetta Ferretti

03/05/2021 - nowadays

OMCEO, Oncologic Commission, Onco-geriatric sub commission in collaboration with GOGI – Onlus (Italian Group of Geriatric Oncology). Coordinator: dr. Vincenzo Bianco

12/2017 – 12/2022

University of Rome “La Sapienza”, Division of Radiological, Oncological and Pathological science.

Doctor in specialist training in Medical Oncology.

Experimental degree “5-fluoro-uracil Degradation Rate Study in pseudo-adjuvant treatment population”. Supervisor: prof.ssa Federica Mazzuca

Vote 70/70 cum laude

29/12/2017 – 28/12/2022

Member of Multidisciplinary board “Geriatric Oncology” (UMOG, Pol. Umberto 1). Coordinator: dr. Vincenzo Bianco

03/10/2016 – 30/06/2017

Internship

Pediatric Hospital Bambino Gesù, Allergology Unit, head physician: Dott. A. Fiocchi

17/03/2016

Medical register in Rome, position number: OMCEO Roma M62285

11/2015 – 01/2016

University of Rome “La Sapienza”

Medical license acquired

Ottobre 2009 – settembre 2015

University of Rome “La Sapienza”, Faculty of Medicine and Psychology.

Degree in Medicine and Surgery.

Experimental Degree "Personalized Medicine in allergic children". Supervisor: Prof.ssa Maria Pia Villa and Prof. Mario Barreto

Vote 110/110 cum laude.

OTHER SCIENTIFIC CERTIFIED ACTIVITIES

Winner of type 1B financing among "Bando di Ateneo 2023 per avvio alla ricerca" with the project "EVALUTATION OF CLINICAL IMPACT OF DRUG-DRUG INTERACTIONS IN METASTATIC COLORECTAL CANCER PATIENTS DURING 5FU-BASED CHEMOTHERAPY USING DRUG-PIN SOFTWARE: A pooled post-hoc analysis of TRIBE and TRIBE2 studies" approved by S.A. 263/2023 on 10.10.2023

12/12/2021 GOOD CLINICAL PRACTICE (GCP) Certificate realized by Nida clinical trials Network

05/07/2022 P.D.T.A. for onco-geriatric patient produced by Oncologic Commission, Onco-geriatric sub commission and validated from Directive board of OMCEO of Rome

26/09/2018 BLS-D Provider – Basic Life Support Defibrillation- AHA

28/11– 2/12/2016 – School of Personalized Medicine – SIMeP 2016 Winter School, Roma

2013-2015 Percorso di Eccellenza in translational medicine at University of Rome "La Sapienza", Faculty Of Medicine and Psychology. Research project "Personalized Medicine in patients with Multiple Chemical Sensibility". Tutor: prof. Guglielmo Bruno and prof. Maurizio Simmaco

CONGRESS AS SPEAKER

- "La gestione in team multidisciplinare del Carcinoma del colon e del retto". Roma, 15/12/2023.
- "Carcinoma della mammella nella paziente anziana - XIV corso di formazione". Roma, 01/12/2023
- "V Congresso di Oncologia dei Castelli Romani". Frascati, 24-25/11/2023
- "Il MEDICO OGGI - Dalla Formazione al Benessere Lavorativo". OMCEO Roma, 20/10/2023
- "Prevenzione e tecnologia multidisciplinare nella medicina moderna: innovazione e progresso al servizio della salute". OMCEO Roma, 07/10/2023
- "Oncogeriatría traslazionale". OMCEO Roma, 15 settembre 2023
- "Approccio multidisciplinare al paziente anziano con carcinoma della prostata: specialisti a confronto". Roma, 17 marzo 2023
- "Approccio multidisciplinare al paziente anziano con carcinoma della prostata: specialisti a confronto". Rome, 02/12/2022
- "La gestione multidisciplinare del Carcinoma del Colon e del Retto nel Paziente anziano". Rome, 01 e 08/04/2022
- "Il carcinoma del colon e del retto nel paziente anziano". Rome, 15/10/2021
- "Il carcinoma della mammella nella paziente anziana". Rome, 01/10/2021
- "Neoplasia del colon-retto: dalla ricerca alla pratica clinica". Rome, 07/07/2021

**CONGRESS AS SCIENTIFIC
COORDINATOR**

- "Il carcinoma della mammella nella paziente anziana". Rome, 11/09/2020
- "Il carcinoma del colon e del retto nel paziente anziano". Rome, 21/10/2019
- "3° RIMOG. State of the Art and Novelties in Geriatric Oncology". Siena, 20/09/2019
- "Novel Clinical strategies in NSCLC". Rome, 9-10/05/2019
- "Il Carcinoma della mammella nella paziente anziana". Rome, 01/02/2019
- "Il paziente oncologico anziano. Gestione e trattamento". Siena, 23/11/2018
- "Focus sul Carcinoma del Colon e del Retto nel paziente anziano: stato dell'arte e opinioni a confronto". Rome, 09/07/2018
- "La gestione in team multidisciplinare del Carcinoma del colon e del retto". Roma, 15/12/2023.
- "Oncogeriatra traslazionale". OMCEO Roma, 15 settembre 2023
- "Approccio multidisciplinare al paziente anziano con carcinoma della prostata: specialisti a confronto". Roma, 17 marzo 2023
- "Approccio multidisciplinare al paziente anziano con carcinoma della prostata: specialisti a confronto". Rome, 02/12/2022
- "La gestione multidisciplinare del Carcinoma del Colon e del Retto nel Paziente anziano". Rome, 01 e 08/04/2022
- "Il carcinoma del colon e del retto nel paziente anziano". Rome, 15/10/2021
- "Il carcinoma del colon e del retto nel paziente anziano". Rome, 21/10/2019

PUBLICATIONS

- Signorelli, C.; Chilelli, M.G.; [...], Fiorenza Santamaria, et al. Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis. *Cancers* 2023, 15, 5758. <https://doi.org/10.3390/cancers15245758>
- Signorelli C., Calegari M.A., [...], Fiorenza Santamaria, et al. Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study. *Curr. Oncol.* 2023, 30, 5456–5469. <https://doi.org/10.3390/curroncol30060413>

ABSTRACT AND POSTER

- Santamaria F., Buccilli D., et al. Real-world data for never resectable mCRC patients during first line chemotherapy - A single Institution experience. *Tumori Journal* 109(2): 138
- Signorelli C., Calegari M.A., [...] Santamaria F., et al. Prognostic and Predictive Effect of Primary Tumor Location on Non-Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Later-Line Refractory Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Experience" November 2023 *Tumori Journal* 109(2):133-134
- Cirillo A., Verrico M., [...] Santamaria F., et al. The impact of immunological age on the response to immunotherapy: a network approach. *Tumori Journal* 109(2): 259

- Caira G., Calegari M., [...] Santamaria F., et al. Efficacy of trifluridine/tipiracil according to extended RAS evaluation: A multicenter retrospective analysis. *Ann. Oncol.* Vol. 34, Suppl.1, S143, June 2023. <https://doi.org/10.1016/j.annonc.2023.04.424>
- Trovato G., Valente G., [...], Santamaria F., et al. Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis. *Ann. Oncol.* Vol. 34, suppl. 1, S140-S141, June 2023. <https://doi.org/10.1016/j.annonc.2023.04.416>
- Signorelli C., Calegari M., [...], Santaria F., et al. Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study. *Ann. Oncol.* Vol. 34, suppl. 1, S85, June 2023. <https://doi.org/10.1016/j.annonc.2023.04.251>
- Signorelli C., Schirripa M., [...] Fiorenza Santamaria, et al. Sequential treatment with regorafenib and trifluridine/tipiracil in later-line refractory metastatic colorectal cancer: A real-world multicenter retrospective study. *Journal of Clinical Oncology* 41, no. 4_suppl (February 01, 2023) 45-45 DOI: 10.1200/JCO.2023.41.4_suppl.45
- Signorelli C., Schirripa M., [...] Fiorenza Santamaria, et al. Effectiveness and Safety of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study with Focus on Sequential Treatment. *Ann Oncol*; Vol. 33; Iss. S7 (2022), <https://doi.org/10.1016/j.annonc.2022.07.536>
- Signorelli C., Schirripa M., ..., Santamaria F., et al. Comparative analysis of Regorafenib and Triflurine/Tipiracil in later line refractory Metastatic Colo Rectal Cancer: a real-life multicenter Retrospective study. *Tumori Journal*, abstract book. Volume 108 Number 4S October 2022. <https://dx.doi.org/10.13140/rg.2.2.18710.01602>
- Borrelli A., Di Lisa F.S., [...], Santamaria F., et al. Impact of baseline systemic inflammation scores in patients with NSCLC treated with immunotherapy: a propensity matched score analysis. *Tumori Journal*, abstract book. Volume 106 Number 2S October 2020
- Sorace C., Di Lisa F.S., [...], Santamaria F., et al. Pneumonia associated with Immune Checkpoint Inhibitors in NSCLC. *Tumori Journal*, abstract book. Volume 106 Number 2S October 2020
- Cristofani L., Di Lisa F.S., [...], Santamaria F., et al. Efficacy and tolerability of immune checkpoint inhibitors in NSCLC: our experience of a single institution. *Tumori Journal*, abstract book. Volume 106 Number 2S October 2020

OTHER INFORMATIONS

2019 – nowadays:
AIOM and ESMO member

PERSONAL SKILLS

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

ENGLISH

Reading skills: excellent; Writing and speaking skills: good.

TECNICAL SKILLS

- Excellent skills in utilization of Office Pack, MedCalc and SPSS. Good skills in using R.
- Excellent capacity in organizing scientific conferences.

EXPERTIZE	<ul style="list-style-type: none"> - Excellent capacity in clinical application of Personalized Medicine, with complex pharmacological treatment optimization integrating genomic and molecular information, clinical and pathological phenotype, anamnestic and demographic data and single patient need. - Excellent clinical oncogeriatric and gastrointestinal cancers management.
GUIDE LICENCE	Patente B

Fiorenza Santamaria herself, abide by the articles 46 and 76 of D.P. R. n.445/00 is aware that false statements are punishable by the Penal Code and special relating laws and declares that what is written on this curriculum vitae corresponds to truth, forcing herself to demonstrate this by presenting all the documents if required.

Fiorenza Santamaria also authorize the use of personal data according to D.Lgs 196/2003 concerning right to privacy of personal information and subsequent modifications concerning right to privacy of personal information.

Rome, 29/01/2024

Fiorenza Santamaria

